Search research articles
Contact Us
Filters
Showing results (1-10 of 22) with videos related to
Page
of 3
Sort By:
Breast Cancer Research and Treatment
|
December 1, 2017
Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer
T Reinert, M Debiasi, J Bines, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2009
What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?
C H Barrios, C Sampaio, J Vinholes, et al.
Oncology
|
January 1, 1992
Evaluation of an implantable venous access system in a general oncology population
C H Barrios, J E Zuke, B Blaes, et al.
Revista Da Associacao Medica Brasileira (1992)
|
September 1, 1995
[Value of CA 125 as a tumor marker in ovarian carcinoma]
C H Barrios, E de P Guedes Neto, P Monteggia, et al.
British Journal of Cancer
|
May 23, 2013
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
R J Motzer, B Escudier, R Bukowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 8, 2020
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial<sup>☆</sup>
F Montemurro, S Delaloge, C H Barrios, et al.
Public Health
|
June 4, 2017
Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region
J Martínez-Mesa, G Werutsky, S Michiels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 18, 2020
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
S Adams, V Diéras, C H Barrios, et al.
ESMO Open
|
May 29, 2025
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial
X Hu, G Curigliano, K Yonemori, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2015
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma
A Ravaud, C H Barrios, B Alekseev, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 22) with videos related to
Sort By:
Page
of 3
Breast Cancer Research and Treatment
|
December 1, 2017
Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer
T Reinert, M Debiasi, J Bines, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2009
What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?
C H Barrios, C Sampaio, J Vinholes, et al.
Oncology
|
January 1, 1992
Evaluation of an implantable venous access system in a general oncology population
C H Barrios, J E Zuke, B Blaes, et al.
Revista Da Associacao Medica Brasileira (1992)
|
September 1, 1995
[Value of CA 125 as a tumor marker in ovarian carcinoma]
C H Barrios, E de P Guedes Neto, P Monteggia, et al.
British Journal of Cancer
|
May 23, 2013
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
R J Motzer, B Escudier, R Bukowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 8, 2020
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial<sup>☆</sup>
F Montemurro, S Delaloge, C H Barrios, et al.
Public Health
|
June 4, 2017
Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region
J Martínez-Mesa, G Werutsky, S Michiels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 18, 2020
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
S Adams, V Diéras, C H Barrios, et al.
ESMO Open
|
May 29, 2025
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial
X Hu, G Curigliano, K Yonemori, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2015
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma
A Ravaud, C H Barrios, B Alekseev, et al.
Page
of 3